418 related articles for article (PubMed ID: 32811190)
1. CGRP inhibitors for migraine prophylaxis: a safety review.
Rivera-Mancilla E; Villalón CM; MaassenVanDenBrink A
Expert Opin Drug Saf; 2020 Oct; 19(10):1237-1250. PubMed ID: 32811190
[TBL] [Abstract][Full Text] [Related]
2. CGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine.
Maasumi K; Michael RL; Rapoport AM
Drugs; 2018 Jun; 78(9):913-928. PubMed ID: 29869205
[TBL] [Abstract][Full Text] [Related]
3. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
Chiang CC; Schwedt TJ
Prog Brain Res; 2020; 255():143-170. PubMed ID: 33008505
[TBL] [Abstract][Full Text] [Related]
4. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
[TBL] [Abstract][Full Text] [Related]
5. Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.
Overeem LH; Raffaelli B; Mecklenburg J; Kelderman T; Neeb L; Reuter U
CNS Drugs; 2021 Aug; 35(8):805-820. PubMed ID: 34272688
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans.
de Vries T; Villalón CM; MaassenVanDenBrink A
Pharmacol Ther; 2020 Jul; 211():107528. PubMed ID: 32173558
[TBL] [Abstract][Full Text] [Related]
7. CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention.
Caronna E; Alpuente A; Torres-Ferrus M; Pozo-Rosich P
Handb Clin Neurol; 2024; 199():107-124. PubMed ID: 38307640
[TBL] [Abstract][Full Text] [Related]
8. [Novel migraine treatment with CGRP-related monoclonal antibodies].
Shibata M
Rinsho Shinkeigaku; 2020 Oct; 60(10):668-676. PubMed ID: 32893246
[TBL] [Abstract][Full Text] [Related]
9. Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.
Hargreaves R; Olesen J
Headache; 2019 Jun; 59(6):951-970. PubMed ID: 31020659
[TBL] [Abstract][Full Text] [Related]
10. Side effects associated with current and prospective antimigraine pharmacotherapies.
González-Hernández A; Marichal-Cancino BA; MaassenVanDenBrink A; Villalón CM
Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):25-41. PubMed ID: 29226741
[TBL] [Abstract][Full Text] [Related]
11. The preclinical discovery and development of atogepant for migraine prophylaxis.
Baraldi C; Beier D; Martelletti P; Pellesi L
Expert Opin Drug Discov; 2024 Jul; 19(7):783-788. PubMed ID: 38856039
[TBL] [Abstract][Full Text] [Related]
12. The CGRP Pathway in Migraine as a Viable Target for Therapies.
Edvinsson L
Headache; 2018 May; 58 Suppl 1():33-47. PubMed ID: 29697153
[TBL] [Abstract][Full Text] [Related]
13. New drugs targeting calcitonin gene-related peptide for the management of migraines.
Tana C; Cipollone F; Giamberardino MA; Martelletti P
Expert Opin Emerg Drugs; 2023 Dec; 28(4):233-240. PubMed ID: 37996401
[TBL] [Abstract][Full Text] [Related]
14. Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials.
Silvestro M; Orologio I; Siciliano M; Trojsi F; Tessitore A; Tedeschi G; Russo A
Expert Opin Emerg Drugs; 2023 Dec; 28(2):79-96. PubMed ID: 37185047
[TBL] [Abstract][Full Text] [Related]
15. Recognizing the role of CGRP and CGRP receptors in migraine and its treatment.
Edvinsson L; Warfvinge K
Cephalalgia; 2019 Mar; 39(3):366-373. PubMed ID: 29020807
[TBL] [Abstract][Full Text] [Related]
16. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
[TBL] [Abstract][Full Text] [Related]
17. Calcitonin Gene-Related Peptide Antagonists for the Prevention of Migraine: Highlights From Pivotal Studies and the Clinical Relevance of This New Drug Class.
Arca K; Reynolds J; Sands KA; Shiue HJ
Ann Pharmacother; 2020 Aug; 54(8):795-803. PubMed ID: 32019317
[No Abstract] [Full Text] [Related]
18. CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications.
Dodick DW
Cephalalgia; 2019 Mar; 39(3):445-458. PubMed ID: 30661365
[TBL] [Abstract][Full Text] [Related]
19. The sense of stopping migraine prophylaxis.
Al-Hassany L; Lyons HS; Boucherie DM; Farham F; Lange KS; Marschollek K; Onan D; Pensato U; Storch E; Torrente A; Waliszewska-Prosół M; Reuter U;
J Headache Pain; 2023 Feb; 24(1):9. PubMed ID: 36792981
[TBL] [Abstract][Full Text] [Related]
20. Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting.
Wattiez AS; Sowers LP; Russo AF
Expert Opin Ther Targets; 2020 Feb; 24(2):91-100. PubMed ID: 32003253
[No Abstract] [Full Text] [Related]
[Next] [New Search]
